Brief: Basilea Pharmaceutica Raises FY 2026 Guidance

Basilea Pharmaceutica AG, Allschwil

18/08/2026 06:21

Aug 18 (Reuters) - BASILEA PHARMACEUTICA AG BSLN.S:
BASILEA PHARMACEUTICA H1 OPERATING EXPENSES CHF -87.4 MILLION
BASILEA PHARMACEUTICA H1 NET INCOME CHF 27.9 MILLION
BASILEA PHARMACEUTICA H1 OPERATING INCOME CHF 31.6 MILLION
BASILEA PHARMACEUTICA H1 PRETAX PROFIT CHF 32.1 MILLION
BASILEA PHARMACEUTICA - RAISING FULL-YEAR 2026 GUIDANCE: OPERATING PROFIT GROWTH OF 40%, DRIVEN BY INCREASE IN TOTAL REVENUES
FY 2026 CRESEMBA AND ZEVTERA REVENUE NOW EXPECTED TO REACH CHF ~210 MILLION
SEES FY TOTAL REVENUE UP AROUND 15% (PREVIOUSLY GUIDED UP 10%)
Source text: ID:nGNE5ZWzfw
Further company coverage: BSLN.S

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))